文献速递心胸血管麻醉术前评估与围术期医学

预防性去甲肾上腺素输注对心脏手术麻醉诱导期严重低血压的影响:EPITUBE随机对照试验

Prophylactic norepinephrine infusion to reduce severe hypotension during induction of anaesthesia in patients undergoing cardiac surgery: a randomised controlled single-centre clinical trial.
PubMed 文献 · Br J Anaesth · 2025-12-11

EPITUBE单中心随机对照试验纳入210例心脏手术患者,比较预防性去甲肾上腺素输注(0.06 μg kg-1 min-1起始,滴定维持MAP 65-80 mm Hg)与按需麻黄碱对全麻诱导和气管插管后严重低血压的影响。主要结局MAP<55 mm Hg发生率两组无差异(43.8% vs 44.8%,OR 0.96,95%CI 0.56-1.66,P=0.99)。去甲肾上腺素组MAP<65 mm Hg发生率更低(63.8% vs 78.1%,OR 0.49,95%CI 0.26-0.90,P=0.02),插管相关并发症和术后结局无差异。

要点

  • 预防性去甲肾上腺素未降低MAP<55 mm Hg的严重低血压发生率
  • 去甲肾上腺素组MAP<65 mm Hg发生率更低(63.8% vs 78.1%)
  • 插管相关并发症及术后结局两组无差异

核心结论

  • 心脏手术患者全麻诱导前以0.06 μg kg-1 min-1起始输注去甲肾上腺素,与按需麻黄碱相比未减少严重低血压(MAP<55 mm Hg)。

研究设计与样本

  • 随机对照单中心临床试验,纳入210例心脏手术患者,按意向治疗分析。
  • 试验组从预给氧开始输注去甲肾上腺素,起始0.06 μg kg-1 min-1,滴定维持MAP 65-80 mm Hg。
  • 对照组MAP<65 mm Hg时给予麻黄碱。
  • 主要结局为MAP<55 mm Hg的发生率。

主要发现

  • 严重低血压(MAP<55 mm Hg)发生率:去甲肾上腺素组43.8% vs 对照组44.8%(OR 0.96,95%CI 0.56-1.66,P=0.99)。
  • MAP<65 mm Hg发生率:去甲肾上腺素组63.8% vs 对照组78.1%(OR 0.49,95%CI 0.26-0.90,P=0.02)。
  • 插管相关并发症发生率:去甲肾上腺素组22.9% vs 对照组32.4%(OR 0.62,95%CI 0.33-1.14,P=0.13)。
  • 术后结局包括急性肾损伤、机械通气时间和ICU住院时间两组无差异。

临床怎么用

  • 心脏手术麻醉诱导期预防性去甲肾上腺素输注未能减少MAP<55 mm Hg的严重低血压,按需麻黄碱仍为合理选择。
  • 预防性去甲肾上腺素可减少MAP<65 mm Hg的发生,但需权衡临床获益。

局限性

  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EPITUBE trial aimed to determine whether a prophylactic infusion of norepinephrine reduced severe hypotension after induction of general anaesthesia and tracheal intubation in patients undergoing cardiac surgery. METHODS: We performed a randomised controlled single-centre clinical trial including patients undergoing cardiac surgery. In the experimental group, infusion of norepinephrine started from the start of preoxygenation at an infusion rate of 0.06 μg kg-1 min-1, secondarily titrated to maintain mean arterial pressure (MAP) between 65 and 80 mm Hg. In the control group, ephedrine was administered if MAP decreased <65 mm Hg. Primary outcome was the occurrence of MAP <55 mm Hg. Secondary measures included tracheal intubation-related complications, postoperative complications, duration of ICU stay, and mortality. RESULTS: Of 210 patients randomised and analysed in the intention-to-treat analysis, the incidence of severe hypotension was not different between the groups: 43.8% in the norepinephrine group vs 44.8% in the control group (odds ratio 0.96, 95% confidence interval [CI] 0.56-1.66, P=0.99). The incidence of MAP <65 mm Hg was lower in the norepinephrine group than in the control group: 63.8% vs 78.1% (odds ratio 0.49, 95% CI 0.26-0.90, P=0.02). The rate of intubation-related complications was not different between the norepinephrine and control groups, 22.9% vs 32.4%, respectively (odds ratio 0.62, 95% CI 0.33-1.14, P=0.13). There was no difference in postoperative outcomes including acute kidney injury, time on ventilator, or length of stay in the ICU. CONCLUSIONS: In patients undergoing cardiac surgery, infusion of norepinephrine before general anaesthesia at a starting dose of 0.06 μg kg-1 min-1 did not reduce severe hypotension compared with on-demand ephedrine. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05335954.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Gaillard C, Breul L, Foucher A, et al. Prophylactic norepinephrine infusion to reduce severe hypotension during induction of anaesthesia in patients undergoing cardiac surgery: a randomised controlled single-centre clinical trial. Br J Anaesth. 2025. PMID: 41381314. doi:10.1016/j.bja.2025.10.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。